TY - JOUR T1 - 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both JF - Evidence Based Medicine JO - Evid Based Med SP - 143 LP - 143 DO - 10.1136/ebm.12.5.143 VL - 12 IS - 5 A2 - , Y1 - 2007/10/01 UR - http://ebm.bmj.com/content/12/5/143.abstract N2 - Campbell IA, Bentley DP, Prescott RJ, et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007;334:674.OpenUrlAbstract/FREE Full Text 
 
 Q In patients with deep vein thrombosis (DVT), pulmonary embolism (PE), or both, what is the optimum duration of oral anticoagulant therapy? Clinical impact ratings IM/Ambulatory care ★★★★★★☆ Haematology ★★★★★★☆ Design: randomised controlled trial (RCT). Allocation: {concealed}*.† Blinding: {unblinded}*.† Follow-up period: 1 year. Setting: 46 hospitals in the UK. Patients: 810 patients ⩾18 years of age (mean age 59 y, 53% men, based on 749 patients) with DVT, PE, or both, who were to receive anticoagulant therapy. Exclusion criteria included DVT or PE in the past 3 years; severe DVT or PE requiring embolectomy or thrombolysis; neoplasia in the past 3 years; polycythaemia, thrombocythaemia, homozygous factor V Leiden, lupus anticoagulant, or deficiency of protein C, protein S, or antithrombin; advanced multiple sclerosis, orthopaedic problems of the lower limbs, or prolonged or continuous immobility for other reasons; allergy to heparin or warfarin; need … ER -